{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:42:26Z","timestamp":1792237346467,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca Pharmaceuticals LP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.032","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:36:50Z","timestamp":1787240210000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acalabrutinib for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7693-7398","authenticated-orcid":false,"given":"Joseph","family":"Pidala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-2901","authenticated-orcid":false,"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-7143","authenticated-orcid":false,"given":"Lynn","family":"Onstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohtesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Desatnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian V.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2600-6390","authenticated-orcid":false,"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2026.08.032_bib0001","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbmt.2015.10.018","article-title":"Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"22","author":"Arora","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.032_bib0002","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/cam4.5209","article-title":"Patient-reported symptom burden and impact on daily activities in chronic graft-versus-host disease","volume":"12","author":"Yu","year":"2023","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.032_bib0003","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3324\/haematol.2018.192930","article-title":"Patient-reported outcomes and health status associated with chronic graft-versus-host disease","volume":"103","author":"Lee","year":"2018","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.jtct.2026.08.032_bib0004","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.032_bib0005","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbmt.2019.10.019","article-title":"Disability related to chronic graft-versus-host disease","volume":"26","author":"Hamilton","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2026.08.032_bib0006","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.032_bib0007","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.032_bib0008","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood.V72.2.546.546","article-title":"Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation","volume":"72","author":"Sullivan","year":"1988","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.032_bib0009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.jtct.2026.08.032_bib0010","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.032_bib0011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2011.05.016","article-title":"Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study","volume":"18","author":"Gilman","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.032_bib0012","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3324\/haematol.2018.195123","article-title":"A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/sirolimus\/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801","volume":"103","author":"Carpenter","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.032_bib0013","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2026.08.032_bib0014","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jtct.2026.08.032_bib0015","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.032_bib0016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.032_bib0017","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jtct.2026.08.032_bib0018","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1182\/bloodadvances.2022007611","article-title":"Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD","volume":"7","author":"Buxbaum","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.032_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2026.08.032_bib0020","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO-25-03104","article-title":"Randomized, placebo-controlled trial of b-cell depletion for prevention of corticosteroid-requiring chronic graft-versus-host disease","volume":"44","author":"Cutler","year":"2026","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jtct.2026.08.032_bib0021","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMc2517629","article-title":"CD19 CAR T-cell therapy for treatment of chronic graft-versus-host disease","volume":"394","author":"Sandhu","year":"2026","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.032_bib0022","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.032_bib0023","doi-asserted-by":"crossref","first-page":"771.e1","DOI":"10.1016\/j.jtct.2022.08.021","article-title":"Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the phase 1\/2 imagine study","volume":"28","author":"Carpenter","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.032_bib0024","doi-asserted-by":"crossref","first-page":"990.e1","DOI":"10.1016\/j.jtct.2021.08.017","article-title":"Ibrutinib in steroid-refractory chronic graft-versus-host disease, a single-center experience","volume":"27","author":"Chin","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.032_bib0025","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/bloodadvances.2024014374","article-title":"Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis","volume":"9","author":"Pidala","year":"2025","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.032_bib0026","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","article-title":"Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia","volume":"21","author":"Stanchina","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"31","key":"10.1016\/j.jtct.2026.08.032_bib0027","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.032_bib0028","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.032_bib0029","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1007\/s00277-024-05921-7","article-title":"Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis","volume":"103","author":"Nunes","year":"2024","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.032_bib0030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.032_bib0031","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.032_bib0032","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.032_bib0033","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:20:49Z","timestamp":1792236049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S2666636726006718"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.032","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acalabrutinib for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}